- Home
- ZGN vs MIRM Comparison
ZGN vs MIRM Comparison
Compare ZGN & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ZGN | MIRM |
|---|---|---|
| Founded | 1910 | 2018 |
| Country | Italy | United States |
| Employees | N/A | N/A |
| Industry | Apparel | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.3B | 7.2B |
| IPO Year | 2021 | 2019 |
Fundamental Metrics
Financial Performance| Metric | ZGN | MIRM |
|---|---|---|
| Price | $11.68 | $98.75 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 13 |
| Target Price | $11.28 | ★ $119.85 |
| AVG Volume (30 Days) | ★ 984.0K | 447.3K |
| Earning Date | 03-20-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.22% | N/A |
| EPS Growth | N/A | ★ 74.59 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $19,138,000.00 |
| Revenue This Year | $5.17 | $26.22 |
| Revenue Next Year | $7.89 | $22.04 |
| P/E Ratio | $25.94 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.64 | $63.23 |
| 52 Week High | $15.95 | $130.00 |
Technical Indicators
Market Signals| Indicator | ZGN | MIRM |
|---|---|---|
| Relative Strength Index (RSI) | 23.38 | 44.80 |
| Support Level | $11.41 | $97.49 |
| Resistance Level | $11.86 | $105.20 |
| Average True Range (ATR) | 0.41 | 3.51 |
| MACD | -0.19 | 0.69 |
| Stochastic Oscillator | 0.00 | 60.01 |
Price Performance
Historical ComparisonAbout ZGN Ermenegildo Zegna N.V.
Ermenegildo Zegna NV designs creates, and distributes luxury menswear and accessories under the Zegna brand, as well as womenswear, menswear, and accessories under the Thom Browne brand. The company operates in three segments: the Zegna segment (comprising three product lines: Zegna Branded Products, Textile, and Third Party Brands); the Thom Browne segment, and the Tom Ford Fashion segment. The company generates the majority of revenue from the Zegna segment.
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.